{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:45:41Z","timestamp":1791027941308,"version":"4.1.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T00:00:00Z","timestamp":1526083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12016-018-8690-3","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T14:05:50Z","timestamp":1526133950000},"page":"179-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Allergic and Immunologic Perspectives of Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"57","author":[{"given":"Kofi","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakrishna","family":"Chintanaboina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,12]]},"reference":[{"key":"8690_CR1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627\u20131640","journal-title":"Lancet"},{"key":"8690_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46\u201354","journal-title":"Gastroenterology"},{"key":"8690_CR3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.gastro.2008.10.032","volume":"136","author":"CA Anderson","year":"2009","unstructured":"Anderson CA, Massey DC, Barrett JC et al (2009) Investigation of Crohn\u2019s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 136:523\u2013529","journal-title":"Gastroenterology"},{"key":"8690_CR4","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke A, McGovern DP, Barrett JC et al (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci. Nat Genet 42:1118\u20131125","journal-title":"Nat Genet"},{"key":"8690_CR5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.coph.2009.09.006","volume":"9","author":"M Fukata","year":"2009","unstructured":"Fukata M, Abreu MT (2009) Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol 9:680\u2013687","journal-title":"Curr Opin Pharmacol"},{"key":"8690_CR6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000228553","volume":"27","author":"PL Lakatos","year":"2009","unstructured":"Lakatos PL (2009) Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 27:215\u2013225","journal-title":"Dig Dis"},{"key":"8690_CR7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","volume":"49","author":"KM Lange de","year":"2017","unstructured":"de Lange KM, Moutsianas L, Lee JC et al (2017) Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 49:256\u2013261","journal-title":"Nat Genet"},{"key":"8690_CR8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA et al (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46\u201354. e42","journal-title":"Gastroenterology"},{"key":"8690_CR9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG et al (2015) The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 12:720\u2013727","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"8690_CR10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","volume":"15","author":"R Shivashankar","year":"2017","unstructured":"Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr (2017) Incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 15(6):857\u2013863","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8690_CR11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.MIB.0000206540.38834.8c","volume":"12","author":"V Nerich","year":"2006","unstructured":"Nerich V et al (2006) Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflamm Bowel Dis 12:218\u2013226","journal-title":"Inflamm Bowel Dis"},{"key":"8690_CR12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1155\/2007\/951526","volume":"21","author":"HJ Freeman","year":"2007","unstructured":"Freeman HJ (2007) Application of the Montreal classification for Crohn\u2019s disease to a single clinician database of 1015 patients. Can J Gastroenterol 21:363\u2013366","journal-title":"Can J Gastroenterol"},{"issue":"4 Pt 1","key":"8690_CR13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0016-5085(75)80270-8","volume":"68","author":"RG Farmer","year":"1975","unstructured":"Farmer RG, Hawk WA, Turnbull RB Jr (1975) Clinical patterns in Crohn\u2019s disease: a statistical study of 615 cases. Gastroenterology 68(4 Pt 1):627","journal-title":"Gastroenterology"},{"issue":"12","key":"8690_CR14","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1111\/j.1572-0241.2000.03361.x","volume":"95","author":"M Pimentel","year":"2000","unstructured":"Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, Lin HC (2000) Identification of a prodromal period in Crohn\u2019s disease but not ulcerative colitis. Am J Gastroenterol 95(12):3458","journal-title":"Am J Gastroenterol"},{"issue":"4 Pt 2","key":"8690_CR15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0016-5085(79)90389-5","volume":"77","author":"HS Mekhjian","year":"1979","unstructured":"Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK (1979) Clinical features and natural history of Crohn\u2019s disease. Gastroenterology. 77(4 Pt 2):898","journal-title":"Gastroenterology."},{"issue":"3","key":"8690_CR16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.suc.2007.03.001","volume":"87","author":"R Thoreson","year":"2007","unstructured":"Thoreson R, Cullen JJ (2007 Jun.) Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am 87(3):575\u2013585","journal-title":"Surg Clin North Am"},{"key":"8690_CR17","doi-asserted-by":"crossref","unstructured":"A. M. C. Faria, D. Mucida, D.-M. McCafferty, N. M. Tsuji, and V. Verhasselt (2012) \u201cTolerance and inflammation at the gut mucosa,\u201d Clinical and Developmental Immunology, vol. 2012, Article ID 738475, pages, 3","DOI":"10.1155\/2012\/738475"},{"key":"8690_CR18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.physiol.010908.163145","volume":"71","author":"LG Flier van der","year":"2009","unstructured":"van der Flier LG, Clevers H (2009) Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 71:241\u2013260","journal-title":"Annu Rev Physiol"},{"key":"8690_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","volume":"13","author":"A Geremia","year":"2014","unstructured":"Geremia A, Biancheri P, Allan P, Corazza GR, Di SA (2014) Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13:3\u201310","journal-title":"Autoimmun Rev"},{"issue":"1","key":"8690_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.autrev.2013.06.004","volume":"13","author":"A Geremia","year":"2014","unstructured":"Geremia A, Biancheri P, Allan P et al (2014) Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13(1):3\u201310","journal-title":"Autoimmun Rev"},{"key":"8690_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/mi.2009.122","volume":"3","author":"A Kaser","year":"2010","unstructured":"Kaser A, Blumberg RS (2010) Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol 3:11\u201316","journal-title":"Mucosal Immunol"},{"key":"8690_CR22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ibd.21403","volume":"17","author":"SY Salim","year":"2011","unstructured":"Salim SY, Soderholm JD (2011) Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 17:362\u2013381","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"8690_CR23","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2353\/ajpath.2006.060681","volume":"169","author":"JR Turner","year":"2006","unstructured":"Turner JR (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169(6):1901\u20131909","journal-title":"Am J Pathol"},{"issue":"1","key":"8690_CR24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ni.1825","volume":"11","author":"NH Salzman","year":"2010","unstructured":"Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sj\u00f6berg J, Amir E, Teggatz P, Barman M, Hayward M, Eastwood D, Stoel M, Zhou Y, Sodergren E, Weinstock GM, Bevins CL, Williams CB, Bos NA (2010) Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 11(1):76","journal-title":"Nat Immunol"},{"issue":"5239","key":"8690_CR25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1126\/science.270.5239.1203","volume":"270","author":"ML Hermiston","year":"1995","unstructured":"Hermiston ML, Gordon JI (1995) Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 270(5239):1203","journal-title":"Science."},{"key":"8690_CR26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/ng.381","volume":"41","author":"JC Barrett","year":"2009","unstructured":"Barrett JC, Lee JC, Lees CW et al (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41:1330\u20131334","journal-title":"Nat Genet"},{"key":"8690_CR27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson CA, Boucher G, Lees CW et al (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43:246\u2013252","journal-title":"Nat Genet"},{"key":"8690_CR28","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.molimm.2007.02.007","volume":"44","author":"A Uehara","year":"2007","unstructured":"Uehara A, Fujimoto Y, Fukase K, Takada H (2007) Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 44:3100\u20133111","journal-title":"Mol Immunol"},{"key":"8690_CR29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00054725-200307000-00001","volume":"9","author":"J Wehkamp","year":"2003","unstructured":"Wehkamp J, Harder J, Weichenthal M et al (2003) Inducible and constitutive betadefensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 9:215\u2013223","journal-title":"Inflamm Bowel Dis"},{"issue":"6837","key":"8690_CR30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/35079114","volume":"411","author":"Y Ogura","year":"2001","unstructured":"Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nu\u00f1ez G, Cho JH (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn\u2019s disease. Nature 411(6837):603","journal-title":"Nature"},{"issue":"6837","key":"8690_CR31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","volume":"411","author":"JP Hugot","year":"2001","unstructured":"Hugot JP, Chamaillard M, Zouali H, Lesage S, C\u00e9zard JP, Belaiche J, Almer S, Tysk C, O\u2019Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn\u2019s disease. Nature 411(6837):599","journal-title":"Nature"},{"issue":"1","key":"8690_CR32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2697","volume":"221","author":"D Glick","year":"2010","unstructured":"Glick D, Barth S, Macleaod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221(1):3\u201312","journal-title":"J Pathol"},{"issue":"10","key":"8690_CR33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nri3532","volume":"13","author":"V Deretic","year":"2013","unstructured":"Deretic V, Saitoh T, Akira S (2013) Autophagy in infection, inflammation and immunity. Nat Rev Immunol 13(10):722\u2013737","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"8690_CR34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/ng1954","volume":"3","author":"J Hampe","year":"2007","unstructured":"Hampe J, Franke A, Rosenstiel P et al (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 3(9):207\u2013211","journal-title":"Nat Genet"},{"key":"8690_CR35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng2061","volume":"39","author":"M Parkes","year":"2007","unstructured":"Parkes M, Barrett JC, Prescott NJ et al (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn\u2019s disease susceptibility. Nat Genet 39:830\u2013832","journal-title":"Nat Genet"},{"issue":"1","key":"8690_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","volume":"94","author":"HC Reinecker","year":"1993","unstructured":"Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94(1):174","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"8690_CR37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.39.5.684","volume":"39","author":"JM Reimund","year":"1996","unstructured":"Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn\u2019s disease. Gut 39(5):684\u2013689","journal-title":"Gut"},{"issue":"6","key":"8690_CR38","first-page":"2269","volume":"118","author":"N Kamada","year":"2008","unstructured":"Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T (2008) Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23\/IFN-gamma axis. J Clin Invest 118(6):2269\u20132280","journal-title":"J Clin Invest"},{"key":"8690_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.iy.12.040194.001303","volume":"12","author":"S Romagnani","year":"1994","unstructured":"Romagnani S (1994) Lymphokine production by human T cells in disease states. Annu Rev Immunol 12:227\u2013257","journal-title":"Annu Rev Immunol"},{"key":"8690_CR40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485\u2013517","journal-title":"Annu Rev Immunol"},{"key":"8690_CR41","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1210\/me.2011-0068","volume":"25","author":"JR Flammer","year":"2011","unstructured":"Flammer JR, Rogatsky I (2011) Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol 25:1075\u20131086","journal-title":"Mol Endocrinol"},{"issue":"2","key":"8690_CR42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","volume":"75","author":"R K\u00fchn","year":"1993","unstructured":"K\u00fchn R, L\u00f6hler J, Rennick D, Rajewsky K, M\u00fcller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75(2):263","journal-title":"Cell"},{"issue":"5","key":"8690_CR43","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0016-5085(99)70392-6","volume":"117","author":"IJ Fuss","year":"1999","unstructured":"Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W (1999) Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117(5):1078","journal-title":"Gastroenterology"},{"issue":"7","key":"8690_CR44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/1074-7613(94)90045-0","volume":"1","author":"F Powrie","year":"1994","unstructured":"Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL (1994) Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1(7):553","journal-title":"Immunity"},{"issue":"15","key":"8690_CR45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, Crohn\u2019s Disease cA2 Study Group (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. N Engl J Med 337(15):1029","journal-title":"N Engl J Med"},{"key":"8690_CR46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","volume":"347","author":"DK Podolsky","year":"2002","unstructured":"Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417\u2013429","journal-title":"N Engl J Med"},{"key":"8690_CR47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4049\/jimmunol.163.1.143","volume":"163","author":"G Monteleone","year":"1999","unstructured":"Monteleone G, Trapasso F, Parrello T et al (1999) Bioactive IL-18 expression is up-regulated in Crohn\u2019s disease. J Immunol 163:143\u2013147","journal-title":"J Immunol"},{"key":"8690_CR48","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou L, Ivanov II, Spolski R et al (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967\u2013974","journal-title":"Nat Immunol"},{"key":"8690_CR49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2004.12.042","volume":"128","author":"G Monteleone","year":"2005","unstructured":"Monteleone G, Monteleone I, Fina D et al (2005) Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn\u2019s disease. Gastroenterology 128:687\u2013694","journal-title":"Gastroenterology"},{"key":"8690_CR50","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/ibd.21238","volume":"16","author":"M Sarra","year":"2010","unstructured":"Sarra M, Monteleone I, Stolfi C et al (2010) Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 16:1332\u20131339","journal-title":"Inflamm Bowel Dis"},{"key":"8690_CR51","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0399-8320(10)70015-4","volume":"34","author":"J. Dor\u00e9","year":"2010","unstructured":"Dore J, Corthier G (2010) The human intestinal microbiota. Gastroenterol Clin Biol 34(Suppl. 1):S7\u2013S15","journal-title":"Gastroent\u00e9rologie Clinique et Biologique"},{"issue":"7415","key":"8690_CR52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"CA Lozupone","year":"2012","unstructured":"Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489(7415):220\u2013230","journal-title":"Nature"},{"issue":"5","key":"8690_CR53","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2009.08.042","volume":"137","author":"MA Hildebrandt","year":"2009","unstructured":"Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen YY, Knight R, Ahima RS, Bushman F, Wu GD (2009) High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137(5):1716\u20131724 e1\u20132","journal-title":"Gastroenterology"},{"key":"8690_CR54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1196\/annals.1326.033","volume":"1072","author":"JV Weinstock","year":"2006","unstructured":"Weinstock JV (2006) Helminths and mucosal immune modulation. Ann N Y Acad Sci 1072:356\u2013364","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"8690_CR55","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","volume":"105","author":"DJ Margolis","year":"2010","unstructured":"Margolis DJ, Fanelli M, Hoffstad O, Lewis JD (2010) Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 105(12):2610","journal-title":"Am J Gastroenterol"},{"key":"8690_CR56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.0105-2896.2005.00291.x","volume":"206","author":"CO Elson","year":"2005","unstructured":"Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT (2005) Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206:260\u2013276","journal-title":"Immunol Rev"},{"issue":"1","key":"8690_CR57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cell.2007.08.017","volume":"131","author":"WS Garrett","year":"2007","unstructured":"Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH (2007) Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131(1):33\u201345","journal-title":"Cell"},{"issue":"34","key":"8690_CR58","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104(34):13780\u201313785","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8690_CR59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J (2006) Reduced diversity of faecal microbiota in Crohn\u2019s disease revealed by a metagenomic approach. Gut 55(2):205\u2013211","journal-title":"Gut"},{"key":"8690_CR60","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/ajg.2012.335","volume":"107","author":"R Hansen","year":"2012","unstructured":"Hansen R, Russell RK, Reiff C et al (2012) Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn\u2019s but not in ulcerative colitis. Am J Gastroenterol 107:1913\u20131922","journal-title":"Am J Gastroenterol"},{"key":"8690_CR61","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","volume":"13","author":"XC Morgan","year":"2012","unstructured":"Morgan XC, Tickle TL, Sokol H et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79","journal-title":"Genome Biol"},{"key":"8690_CR62","first-page":"9(1)","volume":"18","author":"A Moustafa","year":"2018","unstructured":"Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ et al (2018) Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol 18:9(1)","journal-title":"Clin Transl Gastroenterol"},{"issue":"Suppl. 1","key":"8690_CR63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000268128","volume":"27","author":"P Marteau","year":"2009","unstructured":"Marteau P (2009) Bacterial flora in inflammatory bowel disease. Dig Dis 27(Suppl. 1):99\u2013103","journal-title":"Dig Dis"},{"issue":"3","key":"8690_CR64","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1053\/j.gastro.2015.05.041","volume":"149","author":"L Reshef","year":"2015","unstructured":"Reshef L, Kovacs A, Ofer A, Yahav L, Maharshak N, Keren N, Konikoff FM, Tulchinsky H, Gophna U, Dotan I (2015) Pouch inflammation is associated with a decrease in specific bacterial taxa. Gastroenterology 149(3):718\u2013727","journal-title":"Gastroenterology"},{"key":"8690_CR65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13059-015-0637-x","volume":"16","author":"XC Morgan","year":"2015","unstructured":"Morgan XC, Kabakchiev B, Waldron L, Tyler AD, Tickle TL, Milgrom R, Stempak JM, Gevers D, Xavier RJ, Silverberg MS, Huttenhower C (2015) Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease. Genome Biol 16:67","journal-title":"Genome Biol"},{"key":"8690_CR66","first-page":"CD000542","volume":"1","author":"M Zachos","year":"2007","unstructured":"Zachos M, Tondeur M, Griffiths AM (2007) Enteral nutritional therapy for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 1:CD000542","journal-title":"Cochrane Database Syst Rev"},{"key":"8690_CR67","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.2640","volume":"14","author":"JR Brestoff","year":"2013","unstructured":"Brestoff JR, Artis D (2013) Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol 14:676\u2013684","journal-title":"Nat Immunol"},{"issue":"2","key":"8690_CR68","first-page":"423e43","volume":"28","author":"PD Han","year":"1999","unstructured":"Han PD, Burke A, Baldassano RN, Rombeau JL, Lichtenstein GR (1999) Nutrition and inflammatory bowel disease. Gastroenterol Clin N Am 28(2):423e43","journal-title":"Gastroenterol Clin N Am"},{"key":"8690_CR69","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/ajcn\/80.5.1342","volume":"80","author":"E Klement","year":"2004","unstructured":"Klement E, Cohen RV, Boxman J, Joseph A, Reif S (2004) Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 80:1342\u20131352","journal-title":"Am J Clin Nutr"},{"key":"8690_CR70","first-page":"CD000542","volume":"3","author":"M Zachos","year":"2001","unstructured":"Zachos M, Tondeur M, Griffiths AM (2001) Enteral nutritional therapy for inducing remission of Crohn\u2019s disease. Cochrane Database Syst Rev 3:CD000542","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8690_CR71","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MIB.0000000000000638","volume":"22","author":"A Racine","year":"2016","unstructured":"Racine A, Carbonnel F, Chan SS, Hart AR et al (2016) Dietary patterns and risk of inflammatory bowel disease in Europe: results from the EPIC study. Inflamm Bowel Dis 22(2):345\u2013354","journal-title":"Inflamm Bowel Dis"},{"key":"8690_CR72","first-page":"834e42","volume":"39","author":"SSM Chan","year":"2014","unstructured":"Chan SSM, Luben R, Olsen A, Tjonneland A, Kaaks R, Lindgren S et al (2014) Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn\u2019s disease. Aliment Pharmacol Ther 39:834e42","journal-title":"Aliment Pharmacol Ther"},{"key":"8690_CR73","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/ajg.2010.192","volume":"105","author":"P Jantchou","year":"2010","unstructured":"Jantchou P, Morois S, Clavel-Chapelon F et al (2010) Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study. Am J Gastroenterol 105:2195\u20132201","journal-title":"Am J Gastroenterol"},{"key":"8690_CR74","first-page":"776e84","volume":"6","author":"AN Ananthakrishnan","year":"2014","unstructured":"Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Fuchs CS et al (2014) Long-term intake of dietary fat and risk of ulcerative colitis and Crohn\u2019s disease. Gut 6:776e84","journal-title":"Gut"},{"issue":"4","key":"8690_CR75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0148607107031004311","volume":"31","author":"K Vagianos","year":"2007","unstructured":"Vagianos K, Bector S, McConnell J, Bernstein CN (2007) Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 31(4):311","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"2","key":"8690_CR76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ibd.20309","volume":"14","author":"JM Phelip","year":"2008","unstructured":"Phelip JM, Ducros V, Faucheron JL, Flourie B, Roblin X (2008) Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis 14(2):242","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"8690_CR77","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1097\/MIB.0000000000000546","volume":"21","author":"R Pinto Del","year":"2015","unstructured":"Del Pinto R, Peitrapaoli D, Chadar AK et al (2015) Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis 21(11):2708\u20132717","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"8690_CR78","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1128\/IAI.00353-08","volume":"76","author":"JH White","year":"2008","unstructured":"White JH (2008) Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun 76(9):3837\u20133843","journal-title":"Infect Immun"},{"issue":"6","key":"8690_CR79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.mam.2008.05.004","volume":"29","author":"F Baeke","year":"2008","unstructured":"Baeke F, van Etten E, Gysemans C, Overbergh L, Mathieu C (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Asp Med 29(6):376\u2013387","journal-title":"Mol Asp Med"},{"key":"8690_CR80","doi-asserted-by":"crossref","unstructured":"Ardesia M, Ferlazzo G, Fries W. Vitamin D and inflammatory bowel disease. Biomed Res In. 2015","DOI":"10.1155\/2015\/470805"},{"issue":"12","key":"8690_CR81","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1097\/01.MIB.0000436957.77533.b2","volume":"19","author":"M Garg","year":"2013","unstructured":"Garg M, Rosella O, Lubel JS, Gibson PR (2013) Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis 19(12):2634\u20132643","journal-title":"Inflamm Bowel Dis"},{"key":"8690_CR82","unstructured":"Kabbani TA, Koutroubakis IE et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study"},{"issue":"Suppl 1","key":"8690_CR83","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1086\/315916","volume":"182","author":"AS Prasad","year":"2000","unstructured":"Prasad AS (2000) Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis 182(Suppl 1):S62\u2013S68","journal-title":"J Infect Dis"},{"key":"8690_CR84","first-page":"116","volume":"48","author":"A Ojuawo","year":"2002","unstructured":"Ojuawo A, Keith L (2002) The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med 48:116\u2013119","journal-title":"Cent Afr J Med"},{"key":"8690_CR85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MPG.0b013e31826a105d","volume":"56","author":"RH Alkhouri","year":"2013","unstructured":"Alkhouri RH, Hashmi H, Baker RD et al (2013) Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 56:89\u201392","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"8690_CR86","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MIB.0000000000000989","volume":"23","author":"S Siva","year":"2017","unstructured":"Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J (2017) Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease. Inflamm Bowel Dis 23(1):152\u2013157","journal-title":"Inflamm Bowel Dis"},{"key":"8690_CR87","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/ije\/dyv301","volume":"44","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN, Khalili H, Song M, Higuchi LM, Richter JM, Chan AT (2015) Zinc intake and risk of Crohn\u2019s disease and ulcerative colitis: a prospective cohort study. Int J Epidemiol 44:1995\u20132005","journal-title":"Int J Epidemiol"},{"issue":"6","key":"8690_CR88","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2007.03431.x","volume":"26","author":"P Dziechciarz","year":"2007","unstructured":"Dziechciarz P, Horvath A, Shamir R, Szajewska H (2007) Meta-analysis: enteral nutrition in active Crohn\u2019s disease in children. Aliment Pharmacol Ther 26(6):795\u2013806","journal-title":"Aliment Pharmacol Ther"},{"key":"8690_CR89","first-page":"CD005984","volume":"3","author":"AK Akobeng","year":"2007","unstructured":"Akobeng AK, Thomas AG (2007) Enteral nutrition for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 3:CD005984","journal-title":"Cochrane Database Syst Rev"},{"key":"8690_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-015-2348-x","volume":"31","author":"M Nakahigashi","year":"2016","unstructured":"Nakahigashi M, Yamamoto T, Sacco R, Hanai H, Kobayashi F (2016) Enteral nutrition for maintaining remission in patients with quiescent Crohn\u2019s disease: current status and future perspectives. Int J Color Dis 31:1\u20137","journal-title":"Int J Color Dis"},{"issue":"Suppl 1","key":"8690_CR91","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","volume":"55","author":"SP Travis","year":"2006","unstructured":"Travis SP, Stange EF, L\u00e9mann M, Oresland T, Chowers Y, Forbes A et al (2006) European evidence based consensus on the diagnosis and management of Crohn\u2019s disease: current management. Gut 55(Suppl 1):i16\u2013i35","journal-title":"Gut"},{"issue":"2","key":"8690_CR92","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/ped.12494","volume":"57","author":"M Konno","year":"2015","unstructured":"Konno M, Takahashi M, Toita N, Fujiwara S, Nojima M (2015) Long-term therapeutic effectiveness of maintenance enteral nutrition for Crohn\u2019s disease. Pediatr Int 57(2):276\u2013280","journal-title":"Pediatr Int"},{"issue":"12","key":"8690_CR93","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/apt.12770","volume":"39","author":"K Frivolt","year":"2014","unstructured":"Frivolt K, Schwerd T, Werkstetter KJ, Schwarzer A, Schatz SB, Bufler P, Koletzko S (2014) Repeated exclusive enteral nutrition in the treatment of paediatric Crohn\u2019s disease: predictors of efficacy and outcome. Aliment Pharmacol Ther 39(12):1398\u20131407","journal-title":"Aliment Pharmacol Ther"},{"issue":"43","key":"8690_CR94","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.3748\/wjg.v19.i43.7652","volume":"19","author":"CL Wall","year":"2013","unstructured":"Wall CL, Day AS, Gearry RB (2013) Use of exclusive enteral nutrition in adults with Crohn\u2019s disease: a review. World J Gastroenterol 19(43):7652\u20137660","journal-title":"World J Gastroenterol"},{"issue":"9","key":"8690_CR95","first-page":"995","volume":"52","author":"Q Yang","year":"2017","unstructured":"Yang Q, Gao X, Chen H, Li M, Wu X, Zhi M, Lan P, Hu P (2017) Efficacy of exclusive enteral nutrition in complicated Crohn\u2019s disease. Scand J Gastroenterol 52(9):995\u20131001","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"8690_CR96","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96(4):1116","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"8690_CR97","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0016-5085(90)90839-S","volume":"98","author":"KM Das","year":"1990","unstructured":"Das KM, Vecchi M, Sakamaki S (1990) A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 98(2):464","journal-title":"Gastroenterology"},{"issue":"3","key":"8690_CR98","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1053\/gast.2002.35396","volume":"123","author":"TR Orchard","year":"2002","unstructured":"Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP (2002) Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123(3):714","journal-title":"Gastroenterology"},{"issue":"9","key":"8690_CR99","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","volume":"23","author":"E Ruocco","year":"2009","unstructured":"Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G (2009) Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 23(9):1008\u20131017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Sup1","key":"8690_CR100","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/jowc.2018.27.Sup1.S4","volume":"27","author":"SE Sasor","year":"2018","unstructured":"Sasor SE, Soleimani T, Chu MW, Cook JA, Nicksic PJ, Tholpady SS (2018) Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J Wound Care 27(Sup1):S4\u2013S8","journal-title":"J Wound Care"},{"key":"8690_CR101","unstructured":"Powell FC, Hackett BC, Wallach D. Pyoderma gangrenosum. In: Fitzpatrick\u2019s dermatology in general medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al (Eds), McGraw-Hill Companies, Inc., New York 2012. Vol 1, p.371"},{"issue":"8","key":"8690_CR102","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/hmg\/11.8.961","volume":"11","author":"CA Wise","year":"2002","unstructured":"Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11(8):961","journal-title":"Hum Mol Genet"},{"issue":"6","key":"8690_CR103","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2013.2907","volume":"149","author":"AV Marzano","year":"2013","unstructured":"Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C (2013) Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol 149(6):762","journal-title":"JAMA Dermatol"},{"issue":"6","key":"8690_CR104","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","volume":"165","author":"AM Binus","year":"2011","unstructured":"Binus AM, Qureshi AA, Li VW, Winterfield LS (2011) Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 165(6):1244","journal-title":"Br J Dermatol"},{"issue":"2","key":"8690_CR105","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.09.040","volume":"78","author":"FD Xia","year":"2018","unstructured":"Xia FD, Liu K, Lockwood S, Butler D, Tsiaras WG, Joyce C, Mostaghimi A (2018) Risk of developing pyoderma gangrenosum after procedures in patients with a known history of pyoderma gangrenosum\u2014a retrospective analysis. J Am Acad Dermatol 78(2):310\u2013314 e1","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8690_CR106","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16401","volume":"180","author":"F. Jockenh\u00f6fer","year":"2018","unstructured":"Jockenh\u00f6fer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2018. doi: https:\/\/doi.org\/10.1111\/bjd.16401","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"8690_CR107","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdcr.2017.08.009","volume":"4","author":"PA Leiphart","year":"2017","unstructured":"Leiphart PA, Lam CC, Foulke GT (2017) Suppression of pathergy in pyoderma gangrenosum with infliximab allowing for successful tendon debridement. JAAD Case Rep. 4(1):98\u2013100","journal-title":"JAAD Case Rep."},{"issue":"1","key":"8690_CR108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archdermatol.2010.393","volume":"147","author":"L Cleach Le","year":"2011","unstructured":"Le Cleach L, Moguelet P, Perrin P, Chosidow O (2011) Is topical monotherapy effective for localized pyoderma gangrenosum? Arch Dermatol 147(1):101\u2013103","journal-title":"Arch Dermatol"},{"issue":"2","key":"8690_CR109","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","volume":"53","author":"J Reichrath","year":"2005","unstructured":"Reichrath J, Bens G, Bonowitz A, Tilgen W (2005) Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 53(2):273\u2013283","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8690_CR110","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, Forbes A, Greenwood R, Probert CS (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505","journal-title":"Gut"},{"key":"8690_CR111","doi-asserted-by":"crossref","unstructured":"Song H, Lahood N, Mostaghimi A (2017) Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol. 5","DOI":"10.1111\/bjd.15850"},{"key":"8690_CR112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archderm.1985.01660010098029","volume":"121","author":"HM Hale Van","year":"1985","unstructured":"Van Hale HM, Rogers RS, Zone JJ, Philip R, Greipp R (1985) Pyostomatitis vegetans\u2014a reactive mucosal marker for inflammatory disease of the gut. Arch Dermatol 121:94\u201398","journal-title":"Arch Dermatol"},{"issue":"3","key":"8690_CR113","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jaad.2016.03.047","volume":"75","author":"LG Clark","year":"2016","unstructured":"Clark LG, Tolkachjov SN, Bridges AG, Camilleri MJ (2016) Pyostomatitis vegetans (PSV)-pyodermatitis vegetans (PDV): a clinicopathologic study of 7 cases at a tertiary referral center. J Am Acad Dermatol 75(3):578\u2013584","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8690_CR114","first-page":"250","volume":"7","author":"S NIgen","year":"2003","unstructured":"NIgen S, Poulin Y, Rochette L, Levesque MH, Gagne E (2003) Pyodermatitis-pyostomatitis vegetans: two cases and a review of the literature. J Cutan Med Surg 7(3):250\u2013255","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"8690_CR115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2230.2004.01438.x","volume":"29","author":"AM Hegarty","year":"2004","unstructured":"Hegarty AM, Barett AW, Scully C (2004) Pyostomatitis vegetans. Clin Exp Dermatol 29(1):1\u20137","journal-title":"Clin Exp Dermatol"},{"key":"8690_CR116","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0714.1992.tb00996.x","volume":"21","author":"MH Thornhill","year":"1992","unstructured":"Thornhill MH, Zakrzewska JM, Gilkes JJH (1992) Pyostomatitis vegetans: report of three cases and review of the literature. J Oral Pathol Med 21:128\u2013133","journal-title":"J Oral Pathol Med"},{"key":"8690_CR117","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S1079-2104(99)70216-7","volume":"87","author":"ML Soriano","year":"1999","unstructured":"Soriano ML, Martinez N, Grilli R, Farina MC, Martin L, Requena L (1999) Pyodermatitis-pyostomatitis vegetans. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87:322\u2013326","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"8690_CR118","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0190-9622(94)70167-9","volume":"31","author":"GS Storwick","year":"1994","unstructured":"Storwick GS, Prihoda MB, Fulton RJ, Wood WS (1994) Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol 31:336\u2013341","journal-title":"J Am Acad Dermatol"},{"key":"8690_CR119","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0190-9622(89)80040-4","volume":"21","author":"FS Ballo","year":"1989","unstructured":"Ballo FS, Camisa C, Allen CM (1989) Pyostomatitis vegetans: report of a case and review of the literature. J Am Acad Dermatol 21:381\u2013387","journal-title":"J Am Acad Dermatol"},{"key":"8690_CR120","first-page":"2016","volume":"20","author":"R Lopes Ca\u00e7ola","year":"2016","unstructured":"Lopes Ca\u00e7ola R, Soares M, Cardoso C, Furtado A (2016) Sweet\u2019s syndrome complicating ulcerative colitis: a rare association. BMJ Case Rep 20:2016","journal-title":"BMJ Case Rep"},{"key":"8690_CR121","unstructured":"Cohen PR, Hongsmann H, Kurzrock R (2012) Acute febrile neutrophilic dermatosis (Sweet syndrome). In: Fitzpatrick\u2019s dermatology in general medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill, Vol 1, p.362"},{"issue":"3","key":"8690_CR122","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clindermatol.2016.02.005","volume":"34","author":"CS Yang","year":"2016","unstructured":"Yang CS, Teeple M, Muglia J, Robinson-Bostom L (2016) Inflammatory and glandular skin disease in pregnancy. Clin Dermatol 34(3):335\u2013343","journal-title":"Clin Dermatol"},{"issue":"1","key":"8690_CR123","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0738-081X(93)90112-P","volume":"11","author":"PR Cohen","year":"1993","unstructured":"Cohen PR, Kurzrock R (1993) Sweet\u2019s syndrome and cancer. Clin Dermatol 11(1):149\u2013157","journal-title":"Clin Dermatol"},{"issue":"4","key":"8690_CR124","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaad.2013.06.023","volume":"69","author":"NM Rochet","year":"2013","unstructured":"Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE (2013) Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol 69(4):557","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"8690_CR125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1203475417690719","volume":"21","author":"JR Casarin Costa","year":"2017","unstructured":"Casarin Costa JR, Virgens AR, de Oliveira ML, Dias NF, Samorano LP, Valente NYS, Festa NC (2017) Sweet syndrome: clinical features, histopathology, and associations of 83 cases. J Cutan Med Surg 21(3):211\u2013216","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"8690_CR126","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/ijd.13232","volume":"55","author":"M Amouri","year":"2016","unstructured":"Amouri M, Masmoudi A, Ammar M, Boudaya S, Khabir A, Boudawara T, Turki H (2016) Sweet\u2019s syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol 55(9):1033\u20131039","journal-title":"Int J Dermatol"},{"issue":"6","key":"8690_CR127","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0190-9622(98)70266-X","volume":"39","author":"AS Giasuddin","year":"1998","unstructured":"Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY (1998) Sweet\u2019s syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 39(6):940","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"8690_CR128","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-4632.2004.02287.x","volume":"44","author":"S Voelter-Mahlknecht","year":"2005","unstructured":"Voelter-Mahlknecht S, Bauer J, Metzler G, Fierlbeck G, Rassner G (2005) Bullous variant of Sweet\u2019s syndrome. Int J Dermatol 44(11):946\u2013947","journal-title":"Int J Dermatol"},{"issue":"3","key":"8690_CR129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-0609.1992.tb00924.x","volume":"49","author":"A Mijovic","year":"1992","unstructured":"Mijovic A, Novak A, Medenica L (1992) Sweet\u2019s syndrome associated with inversion of chromosome 3q in a patient with refractory anemia. Eur J Haematol 49(3):156\u2013157","journal-title":"Eur J Haematol"},{"issue":"9","key":"8690_CR130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-4632.2009.04422.x","volume":"49","author":"H Takahama","year":"2010","unstructured":"Takahama H, Kanbe T (2010) Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet\u2019s syndrome. Int J Dermatol 49(9):1079\u20131080","journal-title":"Int J Dermatol"},{"issue":"7","key":"8690_CR131","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMc1412998","volume":"372","author":"T Jo","year":"2015","unstructured":"Jo T, Horio K, Migita K (2015) Sweet\u2019s syndrome in patients with MDS and MEFV mutations. N Engl J Med 372(7):686","journal-title":"N Engl J Med"},{"issue":"2","key":"8690_CR132","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00128071-200203020-00005","volume":"3","author":"PR Cohen","year":"2002","unstructured":"Cohen PR, Kurzrock R (2002) Sweet\u2019s syndrome: a review of current treatment options. Am J Clin Dermatol 3(2):117\u2013131","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"8690_CR133","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdcr.2015.03.002","volume":"1","author":"L Seminario-Vidal","year":"2015","unstructured":"Seminario-Vidal L, Guerrero C, Sami N (2015]) Refractory Sweet\u2019s syndrome successfully treated with rituximab. JAAD Case Rep 1(3):123\u2013125","journal-title":"JAAD Case Rep"},{"issue":"3","key":"8690_CR134","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3892\/mco.2015.715","volume":"4","author":"SM Hashemi","year":"2016","unstructured":"Hashemi SM, Fazeli SA, Vahedi A, Golabchifard R (2016) Rituximab for refractory subcutaneous Sweet\u2019s syndrome in chronic lymphocytic leukemia: a case report. Mol Clin Oncol 4(3):436\u2013440","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"8690_CR135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamadermatol.2016.0503","volume":"152","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Barrow W, Selim MA, Nicholas MW (2016) Refractory subcutaneous sweet syndrome treated with adalimumab. JAMA Dermatol. 152(7):842","journal-title":"JAMA Dermatol."},{"issue":"5","key":"8690_CR136","first-page":"313","volume":"70","author":"K Muhammed","year":"2004","unstructured":"Muhammed K, Nandakumar G, Thomas S (2004) Granulomatous cheilitis evolving into Melkersson-Rosenthal syndrome with bilateral facial palsy. Indian J Dermatol Venereol Leprol 70(5):313\u2013314","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"8690_CR137","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1525-1470.1999.99012.x","volume":"16","author":"W Dummer","year":"1999","unstructured":"Dummer W, Lurz C, Jeschke R, Meissner N et al (1999) Granulomatous cheilitis and Crohn\u2019s disease in a 3-year-old boy. Pediatr Dermatol 16(1):39\u201342","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"8690_CR138","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ajg.2015.378","volume":"111","author":"AM Oliveira","year":"2016","unstructured":"Oliveira AM, Martins M, Martins A, Ramos de Deus J (2016) Granulomatous cheilitis associated with Crohn\u2019s disease. Am J Gastroenterol 111(4):456","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"8690_CR139","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00054725-200606000-00011","volume":"12","author":"A White","year":"2006","unstructured":"White A, Nunes C, Escudier M, Lomer MC, Barnard K, Shirlaw P et al (2006) Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. Inflamm Bowel Dis 12(6):508\u2013514","journal-title":"Inflamm Bowel Dis"},{"key":"8690_CR140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1346-8138.2008.00455.x","volume":"35","author":"S Inui","year":"2008","unstructured":"Inui S, Itami S, Katayama I (2008) Granulomatous cheilitis successfully treated with roxithromycin. J Dermatol 35:244\u2013245","journal-title":"J Dermatol"},{"issue":"4","key":"8690_CR141","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0030-4220(91)90555-Q","volume":"72","author":"PM Williams","year":"1991","unstructured":"Williams PM, Greenberg MS (1991) Management of cheilitis granulomatosa. Oral Surg Oral Med Oral Pathol 72(4):436\u2013439","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"3","key":"8690_CR142","first-page":"374","volume":"4","author":"LR Fdez-Freire","year":"2005","unstructured":"Fdez-Freire LR, Serrano Gotarredona A, Bernabeu Wittel J, Pulpillo Ruiz A, Cabrera R, Navarrete Ortega M et al (2005) Clofazimine as elective treatment for granulomatous cheilitis. J Drugs Dermatol 4(3):374\u2013377","journal-title":"J Drugs Dermatol"},{"key":"8690_CR143","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt.791","volume":"102","author":"P Hindryckx","year":"2017","unstructured":"Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S (2017) Infection risk with biologic therapy in patients with inflammatory bowel disease. Clin Pharmacol Ther 102:633\u2013641","journal-title":"Clin Pharmacol Ther"},{"key":"8690_CR144","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000001049","volume":"357","author":"ED Shah","year":"2017","unstructured":"Shah ED, Farida JP, Siegel CA et al (2017) Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis 357:570\u2013577","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"8690_CR145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005176-200502000-00026","volume":"40","author":"M Thayu","year":"2005","unstructured":"Thayu M, Markowitz JE, Mamula P et al (2005) Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40(2):220\u2013222","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8690_CR146","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"357","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM et al (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 357:1617\u20131625","journal-title":"Lancet"},{"key":"8690_CR147","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rdc.2016.09.006","volume":"357","author":"R Seror","year":"2017","unstructured":"Seror R, Mariette X (2017) Malignancy and the risks of biologic therapies: current status. Rheum Dis Clin North Am 357:43\u201364","journal-title":"Rheum Dis Clin North Am"},{"key":"8690_CR148","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","volume":"357","author":"J Axelrad","year":"2016","unstructured":"Axelrad J, Bernheim O, Colombel JF et al (2016) Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 357:58\u201364","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"8690_CR149","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-017-3884-2","volume":"37","author":"O Shovman","year":"2018","unstructured":"Shovman O, Tamar S et al (2018) Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature. Clin Rheumatol 37(2):563\u2013568","journal-title":"Clin Rheumatol"},{"issue":"4","key":"8690_CR150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E (2017) CNS demyelination with TNF-\u03b1 blockers. Curr Neurol Neurosci Rep 17(4):36","journal-title":"Curr Neurol Neurosci Rep"},{"key":"8690_CR151","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M15-0729","volume":"357","author":"I Cleynen","year":"2016","unstructured":"Cleynen I, Van Moerkercke W, Billiet T et al (2016) Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 357:10\u201322","journal-title":"Ann Intern Med"},{"key":"8690_CR152","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","volume":"357","author":"I Guerra","year":"2016","unstructured":"Guerra I, P\u00e9rez-Jeldres T, Iborra M et al (2016) Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 357:894\u2013901","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"8690_CR153","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.anai.2015.06.004","volume":"115","author":"AA Mourad","year":"2015","unstructured":"Mourad AA, Boktor MN, Yilmaz-Demirdag Y, Bahna SL (2015) Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol 115(2):143\u2013146","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"8690_CR154","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00384-007-0395-7","volume":"23","author":"P Rutgeerts","year":"2008","unstructured":"Rutgeerts P, Schreiber S, Feagan B et al (2008) Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn\u2019s disease. Int J Color Dis 23(3):289\u2013296","journal-title":"Int J Color Dis"},{"issue":"12","key":"8690_CR155","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3899\/jrheum.140189","volume":"42","author":"ME Clowse","year":"2015","unstructured":"Clowse ME, Wolf DC, F\u00f6rger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U (2015) Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol 42(12):2270\u20132278","journal-title":"J Rheumatol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-018-8690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-018-8690-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-018-8690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:49:47Z","timestamp":1693669787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-018-8690-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,12]]},"references-count":155,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["8690"],"URL":"https:\/\/doi.org\/10.1007\/s12016-018-8690-3","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,12]]},"assertion":[{"value":"12 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"There are no conflicts of interest relevant to this manuscript. However, for full disclosure, Dr. Clarke is on the speakers\u2019 bureau for AbbVie, Takeda, and Janssen. In addition, he has served on an Ad Board for Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is a review article; no patients were involved, and informed consent was not required. Permission was obtained for all images used and appropriate attribution\/acknowledgement stated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Informed Consent"}},{"value":"Speakers Bureau for Abbvie, Janssen and Takeda; Ad Board for Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}